Motion to Express Support for the AOH 1996 Drug and the Anna Fund Charity

This House recognises that:

• The AOH 1996 drug is a promising new treatment for a rare form of cancer called neuroblastoma.
• Neuroblastoma is a cancer that affects the nervous system, and it is most common in children.
• The AOH 1996 drug works by targeting a protein called proliferating cell nuclear antigen (PCNA), which is essential for the growth and survival of cancer cells.
• Early clinical trials have shown that the AOH 1996 drug is effective in shrinking neuroblastoma tumours and improving survival rates.
• The Anna Fund charity is dedicated to raising money to support research into the AOH 1996 drug and to help patients who are affected by neuroblastoma.

This House urges the government to:

• Show support for the progress that City of Hope has made in developing the AOH 1996 drug.
• Match fund the Anna Fund's fundraising efforts, to send a clear signal of the government's support for this important cause.
• Show cross border solidarity with the Anna Fund and City of Hope, by working with other governments to support research into the AOH 1996 drug and to make it available to patients around the world.

This Motion was submitted by u/Leftywalrus MP CBE 1st Baron Wetwang on behalf of His Majesty’s Most Loyal Opposition.

Opening Speech

Deputy Speaker,

Neuroblastoma is a rare and heart wrenching cancer which predominantly preys on children, inflicting immense suffering and uncertainty. The AOH 1996 drug shines as a beacon of potential amidst this darkness, as it zeroes in on a pivotal protein, proliferating cell nuclear antigen (PCNA), essential for the growth and survival of cancer cells. Preliminary clinical trials offer glimpses of hope, showcasing the drug's capacity to shrink neuroblastoma tumours and elevate survival rates, promising respite to the afflicted.

Simultaneously, the Anna Fund Charity fosters research and support for those grappling with the profound impacts of neuroblastoma. The urgency of our asks becomes evident when considering the wider implications. I ask the government to not only endorse the progress of City of Hope with the AOH 1996 drug but also to channel resources to align with the fundraising endeavours of the Anna Fund Charity. This support signifies a commitment to the cause, enabling enhanced research, improved patient care, and access to treatment.

Furthermore, our call for global collaboration highlights the urgency of the matter. Collaborating with other governments to make the AOH 1996 drug universally available amplifies its potential impact, making strides towards a world where the burden of neuroblastoma is eased for countless families.

I urge the government to support this cause.

This division will end at 10pm on the 20th August.